Allergy Season

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Prescribing Information Patient Information Return to singulair.com

In Chronic Asthma During Allergy Season

In a clinical study involving patients aged >18 years with chronic asthma and allergen sensitivity
SINGULAIR significantly improved asthma symptom control during allergy season3

Study patient population:

  • History of chronic asthma also active during allergy season
  • Skin-test sensitivity to at least 2 of 3 seasonal triggers
Graph of Reduction in Beta-Agonist Use
Graph of Reduction in Daytime Asthma Symptoms
Graph of AM PEFR Increase
Graph of Discontinuation Due to Asthma During Allergy Season

a Adapted from Busse WW, Casale TB, Dykewicz MS, et al. Annals of Allergy, Asthma & Immunology. 2006;96;60–68. Copyright © 2006, American College of Allergy, Asthma & Immunology. All rights reserved.

SINGULAIR also provided:

  • Significant reduction in nighttime asthma symptoms (P<0.001) when compared with placebo
  • Significant improvement in mean change from baseline in pm PEFR (11.3 L/min) when compared with placebo
    (–2.0 L/min) (P<0.001)
  • No significant difference in the percentage of asthma attacksb (2.2%) when compared with placebo (1.7%) (P=NS)

b Asthma attack was defined as any of the following:

  • Emergency department visit
  • Hospital admission
  • Unscheduled office visit
  • Need for oral, intravenous, or intramuscular corticosteroid

Study Design
Study I: A 4-week, multicenter, randomized, placebo-controlled, parallel-group study conducted during the spring allergy season of 455 men and women with chronic asthma for at least 1 year, which was also active during the spring allergy season. Study participants were aged ≥18 years and had an FEV1 of 60% or greater of predicted value.3

SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.

For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.

Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB.

SELECTED SAFETY INFORMATION

  • SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
  • Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
  • Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
  • Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

Before prescribing SINGULAIR, please read the Prescribing Information.

See all references.

20951836(7)-05/10-SNG

For general information and other services for physicians

Merck Services Merck OnCall

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.